BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kokosi MA, Margaritopoulos GA, Wells AU. Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche. Eur Respir Rev 2018;27:170117. [DOI: 10.1183/16000617.0117-2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Ledda RE, Milanese G, Milone F, Leo L, Balbi M, Silva M, Sverzellati N. Interstitial lung abnormalities: new insights between theory and clinical practice. Insights Imaging 2022;13:6. [PMID: 35032230 DOI: 10.1186/s13244-021-01141-z] [Reference Citation Analysis]
2 Gille T, Laveneziana P. Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency. Eur Respir Rev 2021;30:200355. [PMID: 34853093 DOI: 10.1183/16000617.0355-2020] [Reference Citation Analysis]
3 Tsitoura E, Trachalaki A, Vasarmidi E, Mastrodemou S, Margaritopoulos GA, Kokosi M, Fanidis D, Galaris A, Aidinis V, Renzoni E, Tzanakis N, Wells AU, Antoniou KM. Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality. Front Immunol 2021;12:645548. [DOI: 10.3389/fimmu.2021.645548] [Reference Citation Analysis]
4 Trachalaki A, Irfan M, Wells AU. Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert Opin Pharmacother 2021;22:191-204. [PMID: 32993388 DOI: 10.1080/14656566.2020.1822326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kazeminasab S, Emamalizadeh B, Jouyban A, Shoja MM, Khoubnasabjafari M. Macromolecular biomarkers of chronic obstructive pulmonary disease in exhaled breath condensate. Biomark Med 2020;14:1047-63. [PMID: 32940079 DOI: 10.2217/bmm-2020-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Cottin V, Valenzuela C. Diagnostic approach of fibrosing interstitial lung diseases of unknown origin. Presse Med 2020;49:104021. [PMID: 32437843 DOI: 10.1016/j.lpm.2020.104021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Choi B, Kawut SM, Raghu G, Hoffman E, Tracy R, Madahar P, Bernstein EJ, Barr RG, Lederer DJ, Podolanczuk A. Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis. ERJ Open Res 2020;6:00115-2019. [PMID: 32154292 DOI: 10.1183/23120541.00115-2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Vece TJ, Esther CR. Identifying Biomarkers in Pediatric Rare Lung Disease. chILD Grows Up. Am J Respir Crit Care Med 2019;200:1458-9. [PMID: 31454262 DOI: 10.1164/rccm.201908-1594ED] [Reference Citation Analysis]
9 Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, Vrugt B, Feghali-Bostwick CA, Schibli R, Distler O, Mueller C, Maurer B. Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2. Ann Rheum Dis 2019;78:218-27. [PMID: 30448769 DOI: 10.1136/annrheumdis-2018-214322] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]